Literature DB >> 21993618

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations.

Sha Tang1, Elliot L Dimberg, Margherita Milone, Lee-Jun C Wong.   

Abstract

The aim of the study was to determine the prevalence of MNGIE-like phenotype in patients with recessive POLG1 mutations. Mutations in the POLG1 gene, which encodes for the catalytic subunit of the mitochondrial DNA polymerase gamma essential for mitochondrial DNA replication, cause a wide spectrum of mitochondrial disorders. Common phenotypes associated with POLG1 mutations include Alpers syndrome, ataxia-neuropathy syndrome, and progressive external ophthalmoplegia (PEO). Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder characterized by severe gastrointestinal dysmotility, cachexia, PEO and/or ptosis, peripheral neuropathy, and leukoencephalopathy. MNGIE is caused by TYMP mutations. Rare cases of MNGIE-like phenotype have been linked to RRM2B mutations. Recently, POLG1 mutations were identified in a family with clinical features of MNGIE but no leukoencephalopathy. The coding regions and exon-intron boundaries of POLG1 were sequence analyzed in patients suspected of POLG1 related disorders. Clinical features of 92 unrelated patients with two pathogenic POLG1 alleles were carefully reviewed. Three patients, accounting for 3.3% of all patients with two pathogenic POLG1 mutations, were found to have clinical features consistent with MNGIE but no leukoencephalopathy. Patient 1 carries p.W748S and p.R953C; patient 2 is homozygous for p.W748S, and patient 3 is homozygous for p.A467T. In addition, patient 2 has a similarly affected sibling with the same POLG1 genotype. POLG1 mutations may cause MNGIE-like syndrome, but the lack of leukoencephalopathy and the normal plasma thymidine favor POLG1 mutations as responsible molecular defect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993618     DOI: 10.1007/s00415-011-6268-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  Simultaneous detection and quantification of mitochondrial DNA deletion(s), depletion, and over-replication in patients with mitochondrial disease.

Authors:  Ren-Kui Bai; Lee-Jun C Wong
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

2.  A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions.

Authors:  Henna Tyynismaa; Emil Ylikallio; Mehul Patel; Maria J Molnar; Ronald G Haller; Anu Suomalainen
Journal:  Am J Hum Genet       Date:  2009-08-06       Impact factor: 11.025

3.  Gastrointestinal neuromuscular pathology in alpers disease.

Authors:  Raj P Kapur; Corinne Fligner; Bita Maghsoodi; Ronald Jaffe
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

4.  Thymidine phosphorylase mutations cause instability of mitochondrial DNA.

Authors:  Michio Hirano; Clotilde Lagier-Tourenne; Maria L Valentino; Ramon Martí; Yutaka Nishigaki
Journal:  Gene       Date:  2005-07-18       Impact factor: 3.688

5.  Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion.

Authors:  Alice Bourdon; Limor Minai; Valérie Serre; Jean-Philippe Jais; Emmanuelle Sarzi; Sophie Aubert; Dominique Chrétien; Pascale de Lonlay; Véronique Paquis-Flucklinger; Hirofumi Arakawa; Yusuke Nakamura; Arnold Munnich; Agnès Rötig
Journal:  Nat Genet       Date:  2007-05-07       Impact factor: 38.330

6.  Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction.

Authors:  Aurélien Amiot; Maya Tchikviladzé; Francisca Joly; Abdelhamid Slama; Dominique Cazals Hatem; Claude Jardel; Bernard Messing; Anne Lombès
Journal:  Gastroenterology       Date:  2009-04-01       Impact factor: 22.682

7.  Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder.

Authors:  I Nishino; A Spinazzola; M Hirano
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

8.  A new POLG1 mutation with peo and severe axonal and demyelinating sensory-motor neuropathy.

Authors:  L Santoro; F Manganelli; R Lanzillo; A Tessa; F Barbieri; F Pierelli; G Di Giacinto; V Nigro; F M Santorelli
Journal:  J Neurol       Date:  2006-05-24       Impact factor: 4.849

9.  Application of dual-genome oligonucleotide array-based comparative genomic hybridization to the molecular diagnosis of mitochondrial DNA deletion and depletion syndromes.

Authors:  A Craig Chinault; Chad A Shaw; Ellen K Brundage; Lin-Ya Tang; Lee-Jun C Wong
Journal:  Genet Med       Date:  2009-07       Impact factor: 8.822

10.  Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage.

Authors:  Giovanna Pontarin; Artur Fijolek; Paola Pizzo; Paola Ferraro; Chiara Rampazzo; Tullio Pozzan; Lars Thelander; Peter A Reichard; Vera Bianchi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-07       Impact factor: 11.205

View more
  22 in total

Review 1.  Inherited neuropathies: an update.

Authors:  Anna Sagnelli; Giuseppe Piscosquito; Davide Pareyson
Journal:  J Neurol       Date:  2013-09-24       Impact factor: 4.849

Review 2.  Recent advances in clinical neurogenetics.

Authors:  José Berciano
Journal:  J Neurol       Date:  2012-11-16       Impact factor: 4.849

3.  Mapping 136 pathogenic mutations into functional modules in human DNA polymerase γ establishes predictive genotype-phenotype correlations for the complete spectrum of POLG syndromes.

Authors:  Gregory A Farnum; Anssi Nurminen; Laurie S Kaguni
Journal:  Biochim Biophys Acta       Date:  2014-02-07

4.  Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype in a patient with a novel heterozygous POLG mutation.

Authors:  Pankaj Prasun; Dwight D Koeberl
Journal:  J Neurol       Date:  2014-07-15       Impact factor: 4.849

5.  Mitochondrial Neurogastrointestinal Encephalomyopathy Disease in Three Siblings from Pakistan with a Novel Mutation.

Authors:  Sana Durrani; Bee Chin Chen; Yusnita Yakob; Lua Seok Hian; Bushra Afroze
Journal:  J Pediatr Genet       Date:  2018-06-30

Review 6.  Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 7.  Protecting the mitochondrial powerhouse.

Authors:  Morten Scheibye-Knudsen; Evandro F Fang; Deborah L Croteau; David M Wilson; Vilhelm A Bohr
Journal:  Trends Cell Biol       Date:  2014-12-11       Impact factor: 20.808

8.  The role of brain MRI in mitochondrial neurogastrointestinal encephalomyopathy.

Authors:  Mauro Scarpelli; Giuseppe Kenneth Ricciardi; Alberto Beltramello; Isabella Zocca; Francesca Calabria; Anna Russignan; Francesca Zappini; Maria Sofia Cotelli; Alessandro Padovani; Giuliano Tomelleri; Massimiliano Filosto; Paola Tonin
Journal:  Neuroradiol J       Date:  2013-11-07

9.  The DNA Polymerase Gamma R953C Mutant Is Associated with Antiretroviral Therapy-Induced Mitochondrial Toxicity.

Authors:  Min Li; Andrea C Mislak; Yram Foli; Esinam Agbosu; Vivek Bose; Shreya Bhandari; Michal R Szymanski; Christie K Shumate; Y Whitney Yin; Karen S Anderson; Elijah Paintsil
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 10.  POLG-related disorders and their neurological manifestations.

Authors:  Shamima Rahman; William C Copeland
Journal:  Nat Rev Neurol       Date:  2019-01       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.